Filing Flows › Comparisons › ADCT vs TBPH
ADC Therapeutics SA vs Theravance Biopharma: ADCT and TBPH compared
ADC Therapeutics SA is the larger company: $21.7M of revenue in its latest quarter (Q3 2026) against $20.7M for Theravance Biopharma (Q2 2026). ADC Therapeutics SA is growing faster (+32% against -21% a year earlier). Theravance Biopharma is more profitable, with an operating margin of -39.9% against -66.1%.
Where the money goes: ADCT and TBPH
ADC Therapeutics SA (ADCT) · Q3 2026
ADC Therapeutics SA, Q3 2026: revenue $21.7M (+32% year over year), operating margin -66.1%, net loss $25.3M. The chart follows the revenue to costs, profit and cash.
Theravance Biopharma (TBPH) · Q2 2026
Theravance Biopharma, Q2 2026: revenue $20.7M (-21% year over year), operating margin -39.9%, net loss $5.9M, operating cash flow −$7.0M. The chart follows the revenue to costs, profit and cash.
| ADC Therapeutics SA (ADCT) | Theravance Biopharma (TBPH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $21.7M | $20.7M |
| Revenue growth, Y/Y | +32% | -21% |
| Operating margin | -66.1% | -39.9% |
| Net earnings | −$25.3M | −$5.9M |
| Net margin | -116.5% | -28.5% |
| Operating cash flow | — | −$7.0M |
Where the revenue comes from
ADC Therapeutics SA
- Product revenues, net: $21.0M (97%)
- License revenues and royalties: $710K (3%)
Questions
Which is bigger, ADC Therapeutics SA or Theravance Biopharma?
ADC Therapeutics SA is the larger company: $21.7M of revenue in its latest quarter (Q3 2026) against $20.7M for Theravance Biopharma (Q2 2026).
Is ADC Therapeutics SA or Theravance Biopharma growing faster?
ADC Therapeutics SA is growing faster (+32% against -21% a year earlier).
Which is more profitable, ADC Therapeutics SA or Theravance Biopharma?
Theravance Biopharma is more profitable, with an operating margin of -39.9% against -66.1%.
More: ADC Therapeutics SA earnings · how ADC Therapeutics SA makes money · Theravance Biopharma earnings · how Theravance Biopharma makes money
From the companies' latest 10-Q, 10-K or earnings release (8-K filed Nov 9, 2026; 10-Q filed Aug 11, 2026). Fiscal quarters can end on different dates. Not investment advice.